INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10522651		
Filing Date		2005-01-22		
First Named Inventor	Epsh	tein Oleg Iliich		
Art Unit		1646		
Examiner Name	PAK,	MICHAEL D		
Attorney Docket Number		841-007		

	U.S.PATENTS						
Examiner Initial*			Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	5683712		1997-11-04	CAVAZZA		
	2	5879677		1999-03-09	DEL ZOPPO		
	3	4963367		1990-10-16	ECANOW		
	4	5741488		1998-04-21	FELDMAN		
	5	5846514		1998-12-08	FOSTER		
	6	4987127		1991-01-22	SIRANY		
If you wis	h to a	dd additional U.S. Paten	t citatio	n information pl	ease click the Add button.		
			U.S.P	ATENT APPLIC	CATION PUBLICATIONS		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

 Application Number
 10522651

 Filling Date
 2005-01-22

 First Named Inventor
 Epshtein Oleg Illich

 Art Unit
 1646

 Examiner Name
 PAK, MiCHAEL D

 Attorney Docket Number
 841-007

Pages.Columns.Lines

i	1		-			
	1	20070141058		2007-06-21	EPSTEIN et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

#### FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code4	Publication Date	Name of Patentee or Applicant of cited Document	where Relevant Passages or Relevant Figures Appear	T5
	1	2007989	RU	C1	1994-02-28	AKTSIONERNOE OBSHCHESTVO "TREJDIS"		
	2	9412213	wo	A1	1994-06-09	BUCHARDT, Ole et al.		
0	3	2187334	RU	C2	2000-03-10	CHERNOVA O.V.		
	4	9728776	wo	A1	1998-08-04	EPSHTEIN		
	5	9814166	wo	A1	1998-04-09	EPSHTEIN et al.		
	6	9814162	wo	A1	1998-04-09	EPSHTEIN et al.		
	7	9814161	wo	A1	1998-04-09	EPSHTEIN et al.		
	8	9833493	wo	A1	1998-08-06	EPSHTEIN et al.		

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10522651		
Filing Date		2005-01-22		
First Named Inventor	Epsh	tein Oleg Iliich		
Art Unit		1646		
Examiner Name PAK,		MICHAEL D		
Attorney Docket Numb	er	841-007		

9	9835680	wo	A1	1998-08-20	EPSHTEIN et al.	
10	01005371	wo	A1	2001-01-25	EPSHTEIN et al.	
11	2192882	RU	A1	2002-11-20	EPSHTEIN	
12	2177795	RU	A1	2002-01-10	EPSHTEIN	
13	03037372	wo	A1	2003-08-05	EPSHTEIN et al.	
14	03055518	wo	A1	2003-07-10	EPSHTEIN	
15	03077946	wo	A1	2003-09-25	EPSHTEIN	
16	0652014	EP	A1	1995-05-10	NATIONAL INSTITUE OF IMMUNOLOGY	
17	2033784	RU	C1	1995-04-30	INDIVIDUAL'NOE CHASTNOE PREDPRIJATIE "DIALOG"	
18	2122858	RU	C1	1998-12-10	JAKOVLEVA LJUDMILA BORISOVNA	
19	2104032	RU	C1	1998-02-10	Obshchestvo s ogranichennoij otvetstvennosťju	

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10522651
Filing Date		2005-01-22
First Named Inventor	Epsh	tein Oleg Iliich
Art Unit		1646
Examiner Name PAK,		MICHAEL D
Attorney Docket Numb	or	841_007

						The state of the s		
	20	2137483	RU	C1	1999-09-20	BOZHEDOMOV V. A.		
	21	1730144	su		1992-04-30	OVCHARENKO		
	22	9422846	wo		1994-10-13	PRIZER INC.		
	23	0687466	EP	A1	1995-12-20	TAPUACH NATURAL TECH.		
If you wis	h to a	dd additional For				lease click the Add button		
			NON-F	ATENT LIT	ERATURE DO	CUMENTS		
Examine Initials*	Cite No	(book, magazin		symposium,	catalog, etc),	the article (when appropriate), til date, pages(s), volume-issue nur		T5
	1					ted Compounds for Jugulation of Alconch of RAMS, No. 1 (91), 1999	phol Abstinent	
	2	BEREGOVOY et al., "On influence of various Dilutions of Monoclonal Antibodies 5F5-B6 on the Formation of Long- Term Post-Tetanic Potentiation in Survived Hippocampal Slices, Bull of Siberian Branch of RAMS No. 1 (91), 1999						
	3	DAVENAS et al.,	Nature, 1988, 333	816-818.				
	4	EPSHTEIN et al.	May 1999, Bulletin	of Experimer	ntal Biology and	Medicine,Vol. 5: 493-495.		
	5					annykh organnykh preparatov, " LEC ANIZATSIJ V UGOLNOJ PROMYSI		

vyp. 8, 1989, izd. TSNIEHI ugol (Moscow), pp. 163-165.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

RE Filing Date
First Name
Art Unit

10522651 2005-01-22 Epshtein Oleg Iliich

First Named Inventor Epshtein Oleg Iliici
Art Unit 1646

Examiner Name PAK, MICHAEL D

Application Number

Attorney Docket Number

841-007

( Not for submission under 37 CFR 1.99)

	6	International Search Report from International Application No. PCT/RU01/00239, filed June 19, 2001, mailed on September 20, 2001.	
	7	International Search Report from International Application No. PCT/RU02/00365, filed August 2, 2002, mailed on December 5, 2002.	
	8	International Search Report from International Application No. PCT/RU04/000374, filed September 27, 2004, mailed on February 10, 2005.	
	9	International Search Report from International Application No. PCT/RU02/00368, filed August 2, 2002, mailed on December 5, 2002.	
	10	International Search Report from International Application No. PCT/RU02/00369, filed August 2, 2002, mailed on December 19, 2002.	
	11	International Search Report from International Application No. PCT/RU97/00026, filed February 10, 1997, mailed on April 8, 1997.	
	12	IVANIUSHKIN, A. Ja., "Gomeopatiya i sovremennaya medilsina," VESTNIK AKADEMII MEDITSINSKIKH NAUK SSSR, 4, 1988, izd. "Meditsina" (Moscow), pp. 76-82.	
- 6	13	JANEWAY et al. Immunobiology, 1997, 3rd edition, Garland Publishing Inc., pages 3:1-3:11.	
	14	JEGER, J., Ed., "Clinical Immunology and Allergology" (Russian Translation), Meditsina, Moscow, 2000, pp. 358-359.	
	15	KUZNIK, R.I. et al., "Cytomedines and their Role in Regulation of Physiological Functions," Uspekhi Sovremennoi Biologii, 1995, vol. 115, No. 3, pp. 353-367.	
	16	LINDE et al., "Are the clinical effects of homoepathy placebo effects? A meta-analysis of placebo-controlled trials" 1997, Lancet, vol. 350: 834-43.	

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10522651
Filing Date		2005-01-22
First Named Inventor	Epsh	tein Oleg Iliich
Art Unit		1646
Examiner Name	PAK,	MICHAEL D
Attorney Docket Numb	er	841-007

		nitial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a conformance and not considered. Include copy of this form with next communication to applicant.							
Examine	r Signa	ature Date Considered							
		EXAMINER SIGNATURE							
If you wi	sh to a	dd additional non-patent literature document citation information please click the Add button							
	24	VYAZOV, O.L., "Laboratory Methods of Studies in Non-Infection Immunology (in Russian)m Moscow, Meditsina, 1968.							
	23	VASILIEV, Yu, V. et al., "Gomeopatiya: vozrozhdenie traditsionnioy meditsinskoj shkoly," VESTNIK ROSSIJKOJ AKADEMII NAUK, 10, 1992, izd. " Nauka" (Moscow), pp. 145-148.							
	22	STEFANI, D. V. et al., "Immunologiya i immunopatologiya detskogo vozrasta," Moscow, Meditsina, 1996, pp. 28, 29, 358-359.							
	21	SHANG et al., Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoepathy and allopathy" 2005, Lancet, Vol. 366: 726-32.							
	20	SCHWAB, V., "Homeopathic Pharmaceutical Agents. A manual on description and preparation," Moscow, 1967, pp. 12-38.							
	19	Register of Pharmaceuticals of Russia, Encyclopedia of Pharmaceuticals (in Russian), Moscow, 2001, pp. 788-789.							
	18	Register of Pharmaceuticals of Russia, Encyclopedia of Pharmaceuticals (in Russian), Moscow, 2000, pp. 358-359.							
	17	NICKELEIT et al.,"The Classification and treatment of antibody-mediated renal allograft injury: Where do we stand?" 2007, Kid. Int. Vol. 71:7-11							

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.